Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
| ▸ | KDM4A | O75164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1018437 | 0.89 | NR1H4 (0.62) | TSHRSMN1; SMN2NR1H4GAAAPEX1 | |
| SCHEMBL14969490 | 0.88 | TSHR (0.57) | TSHRSMN1; SMN2GAAL3MBTL1NAMPT | |
| SCHEMBL25289892 | 0.88 | APEX1 (0.43) | TSHRSMN1; SMN2NR1H4GAAAPEX1 | |
| SCHEMBL1205128 | 0.87 | NR1H4 (0.48) | TSHRSMN1; SMN2NR1H4GAAAPEX1 | |
| SCHEMBL30910306 | 0.87 | NR1H4 (0.48) | TSHRSMN1; SMN2NR1H4GAAAPEX1 | |
| SCHEMBL30901987 | 0.86 | NR1H4 (0.50) | TSHRSMN1; SMN2NR1H4GAAL3MBTL1 | |
| SCHEMBL14979282 | 0.86 | NR1H4 (0.50) | TSHRSMN1; SMN2NR1H4GAAL3MBTL1 | |
| SCHEMBL8417822 | 0.85 | HDAC1 (0.53) | NR1H4GAAL3MBTL1HDAC1NAMPT | |
| SCHEMBL16415399 | 0.84 | HDAC1 (0.47) | TSHRNR1H4GAAL3MBTL1HDAC1 | |
| SCHEMBL6625230 | 0.84 | NR1H4 (0.50) | TSHRNR1H4GAAL3MBTL1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059172-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL | NIPPON SHINYAKU CO., LTD. (JP) | 2025-02-20 | — | — | US | disclosed |
| EP-4458810-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL | Nippon Shinyaku Co., Ltd. (JP) | 2024-11-06 | — | — | EP | disclosed |
| CN-118748993-A | Indazole compounds and medicaments | 日本新药株式会社 | 2024-10-08 | — | — | CN | disclosed |
| WO-2023127883-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL | 日本新薬株式会社 | 2023-07-06 | — | — | WO | disclosed |
| US-9006257-B2 | Bicyclic compounds as mPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-04-14 | — | — | US | disclosed |
| US-9006257-B2 | Bicyclic compounds as mPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-04-14 | — | — | US | disclosed |
| US-9006257-B2 | Bicyclic compounds as mPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-04-14 | — | — | US | disclosed |
| US-8951999-B2 | Compounds | OREXO AB (SE) | 2015-02-10 | — | — | US | disclosed |
| US-8951999-B2 | Compounds | OREXO AB (SE) | 2015-02-10 | — | — | US | disclosed |
| US-8951999-B2 | Compounds | OREXO AB (SE) | 2015-02-10 | — | — | US | disclosed |
| WO-2013072825-A1 | PHTALAZINONE DERIVATIVES AS MPEGS -1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013072825-A1 | PHTALAZINONE DERIVATIVES AS MPEGS -1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-05-23 | — | — | WO | disclosed |
| EP-2491007-A1 | INHIBITORS OF THE MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1 | Boehringer Ingelheim International GmbH (DE) | 2012-08-29 | — | — | EP | disclosed |
| US-8252831-B2 | Imidazole-2-benzamide compounds useful for the treatment of osteoarthritis | ELI LILLY AND COMPANY (US) | 2012-08-28 | — | — | US | disclosed |
| US-20120157506-A1 | Novel Imidazole-2-Benzamide Compounds Useful for the Treatment of Osteoarthritis | ELI LILLY AND COMPANY (US) | 2012-06-21 | — | — | US | disclosed |
| US-20110263556-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110263556-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110263556-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| WO-2011048004-A1 | INHIBITORS OF THE MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011048004-A1 | INHIBITORS OF THE MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263556-A1 | New Compounds | PTGES, PTGER1, PTGS1 | TSHR 2468/4885SMN1; SMN2 3540/4885NR1H4 248/4885 |
| US-20250059172-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL | MC5R, CYP3A5, PTGIS | TSHR 739/4885SMN1; SMN2 3781/4885NR1H4 1137/4885 |
| US-20120157506-A1 | Novel Imidazole-2-Benzamide Compounds Useful for the Treatment of Osteoarthritis | ARG2, HDAC6, COL2A1 | TSHR 1114/4885SMN1; SMN2 1767/4885NR1H4 1205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.